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ABC = Anemia and blood transfusion in the critically ill; CRIT = Anemia and blood transfusion in the critically ill – Current clinical practice in the
United States; ICU = intensive care unit; RBC = red blood cell.
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Between August 2000 and April 2001, data on red blood cell
(RBC) transfusion and outcome were prospectively collected in
the CRIT study (Anemia and blood transfusion in the critically ill –
Current clinical practice in the United States) in 284 intensive
care units (ICUs) in 213 US hospitals. Data on 4892 patients
were analyzed [1]. The mean pretransfusion hemoglobin was
8.6 ± 1.7 g/dl and did not differ much between surgical ICUs,
medical ICUs and combined ICUs nor between community
ICUs and academic ICUs. Allogeneic RBC transfusions were
independently associated with a longer ICU stay, with a longer
hospital length of stay and with higher mortality. The association
between RBC transfusion and mortality was particularly
pronounced with more than 2 RBC units transfused.
A similar study (the ABC study; Anemia and blood
transfusion in the critically ill) was performed in Europe in
November 1999, which yielded very similar results. The
mean pretransfusion hemoglobin was 8.4 ± 1.3 g/dl, and
the mortality and morbidity were also increased in
transfused patients versus nontransfused patients. This
effect again was clear with more than 2 RBC units
transfused [2].
Both these studies ask two questions: Are allogeneic blood
transfusions beneficial or harmful in intensive care medicine?
How can blood management be improved in intensive care
medicine?
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Abstract
In 284 US intensive care units the CRIT study (Anemia and blood transfusion in the critically ill –
Current clinical practice in the United States) assessed allogeneic red blood cell (RBC) transfusion
and outcome in 4892 patients. As in the former European ABC study (Anemia and blood transfusion in
the critically ill), the mean pretransfusion hemoglobin was approximately 8.5 g/dl and RBC transfusions
were independently associated with an increased mortality. These studies were purely observational
and, therefore, despite the finest statistical models indicating that RBC transfusions were
independently associated with a higher mortality, it remains possible that this adverse outcome is not
due to a harmful effect of RBC transfusion in itself, but merely reflects the fact that transfused patients
were sicker to start with. The definitive call is still out, but one mechanism by which RBC transfusion
might be harmful now appears less likely; namely, storage lesion. In the CRIT study, mortality was not
increased in patients receiving ‘old’ RBCs (>14 days stored) versus ‘fresh’ RBCs. The effect of
leukoreduction could not be assessed since mainly nonleukoreduced RBCs were transfused. The
evidence is mounting, however, that RBC transfusions are efficacious only when oxygen delivery is
compromised. What can be done to diminish the use of RBC transfusions, its costs and side effects in
intensive care medicine? There are two important options available today: decreasing blood loss for
diagnostic purposes using pediatric sampling tubes, and establishing restrictive multidisciplinary
transfusion guidelines and implementing them in daily clinical practice.
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Benefit or harm from allogeneic RBC
transfusion
Both studies are large and data acquisition was prospective,
but the studies are purely observational. Therefore, despite
the finest statistical models used showing that allogeneic
blood transfusions were independently associated with a
higher mortality [1,2], it remains possible that this adverse
outcome is not due to a harmful effect of allogeneic RBC
transfusion in itself, but merely reflects the fact that
transfused patients were sicker to start with. Indeed, there is
some evidence that this was the case.
In the ABC study transfused patients were older, had a lower
baseline hemoglobin, had higher Sepsis-related and Organ
Failure Assessment scores and Acute Physiological and
Chronic Health Evaluation II scores, and were more
frequently in shock at hospital admission [2]. This potential
confounding can only be avoided in prospective, randomized
trials [3,4]. The largest is the study by Hébert and colleagues
comparing a restrictive transfusion regimen (hemoglobin
<7.0 g/dl) with a liberal transfusion regimen (hemoglobin
<9.0 g/dl), finding a lower 30-day mortality in the restrictive
transfusion regimen in patients younger than 55 years of age
and in patients with an Acute Physiological and Chronic
Health Evaluation II score <20 [3]. But also, when combining
all available prospective randomized trials comparing
restrictive and liberal transfusion regimens with mortality data
(n = 1568, referenced in Carson and colleagues [4]), a
higher mortality was found in the liberal transfusion group
(15.2% versus 12.0%, chi-square P < 0.06). The potential is
therefore real that RBC transfusions are efficacious only in
very specific situations in intensive care medicine, such as
when pretransfusion oxygen delivery is low [5], or that RBC
transfusions are associated with significant side effects so
that the overall balance is negative.
Immunosuppressive effects and storage lesions have been
considered potential explanations for the relative
ineffectiveness or even harmfulness of allogeneic blood
transfusions [6,7]. Since the immunosuppressive effect may
be mediated via leukocytes, universal leukoreduction has
been introduced in many countries. Its effect on transfusion-
related side effects, however, was only very modest: post-
transfusion fever decreased but serious nosocomial
infections remained unchanged and the effect on mortality
was borderline [8]. No in-depth information regarding the
type of RBCs transfused and the effect of transfusion on
outcome are available in the CRIT and ABC studies, so this
remains an open question.
In contrast, the age of the transfused RBCs was recorded in
both studies: 16.2 ± 6.7 days in the ABC study [2] and
21.2 ± 11.4 days in the CRIT study [1]. Interestingly, older
blood was not associated with a higher mortality or a higher
morbidity [1,2]. This is in keeping with a recent observational
study in 897 cardiac surgery patients, in which no
association between the age of transfused RBCs and
outcome was observed other than the risk of pneumonia
increases with RBCs older than 28 days [9]. The
mechanism(s) by which potentially harmful effects of
allogeneic blood transfusions are mediated therefore remains
largely unknown.
Improvement of blood management in
intensive care medicine
Given the high costs of allogeneic blood transfusions [10],
their very selective efficacy [5] and their side effects [7], an
improved blood management in intensive care medicine is
mandatory. Such options include decreasing blood loss for
diagnostic purposes using pediatric sampling tubes [2],
establishing restrictive multidisciplinary transfusion guidelines
and implementing them in daily clinical practice [11], using
recombinant human erythropoietin [12] and developing
artificial oxygen carriers [13].
On average, 41 ml blood is drawn each day from a typical
ICU patient. This becomes a main source of blood loss
during the ICU stay [2]. By simply using pediatric sampling
tubes this diagnostic blood loss could easily be cut in half.
This measure is probably too simple to be taken seriously!
Have you introduced it in your ICU?
Establishing restrictive multidisciplinary transfusion guidelines
may also appear trivial. In the real world, however, it is not —
and strictly implementing them in daily clinical practice is
even less so [11]. Interestingly, in the CRIT study the
presence or absence of a transfusion protocol did not
influence the pretransfusion hemoglobin [1]. What does this
mean? Did the transfusion protocols ask for the same
traditional (high) hemoglobin transfusion triggers as used by
the physicians anyway? Or were existing (restrictive)
transfusion guidelines simply neglected? Have you
introduced restrictive transfusion guidelines in your ICU and
meticulously followed physicians’ adherence?
Using recombinant human erythropoietin in intensive
medicine resulted in clear reductions of allogeneic blood
transfusion needs [12]. Its use in daily clinical practice may
be limited by its relatively high price but, sooner or later,
recombinant human erythropoietin will find its place in
intensive care medicine.
Artificial oxygen carriers are fascinating new drugs in clinical
development. Although perioperative transfusion
requirements were reduced in several phase III studies
[13–15], none of these substances is yet licensed in the
Western world for human use and their use in intensive care
medicine is very limited.
So, let us continue to work on future options but let us
simultaneously implement the practical changes that can
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